



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

June 2020





© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

June 2020

N = 7386



Health Authority	Male	Female	All
FRASER	1459	449	1908
INTERIOR	420	103	523
NORTHERN	131	85	216
VANCOUVER COASTAL	3310	456	3766
VANCOUVER ISLAND	787	155	942
	6107	1248	7355
		Unknown/not stated:	31
		Total:	7386

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2015 - June 2020)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (June 2015 - June 2020)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (June 2015 - June 2020)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (June 2015 - June 2020)






1.6 Percent Distribution of Active Participants by CD4 Count (June 2015 - June 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(June 2015 - June 2020)





1.8 Active and Inactive Participants (June 2015 - June 2020)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (June 2015 - June 2020)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (June 2015 - June 2020)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(June 2015 - June 2020)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT
(June 2015 - June 2020)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(June 2015 - June 2020)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (June 2015 - June 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(June 2015 - June 2020)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (June 2015 - June 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(June 2015 - June 2020)






1.18 Baseline CD4 for Antiretroviral First Starts
(June 2015 - June 2020)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (June 2015 - June 2020)






1.20 Cumulative Resistance Testing Results by Resistance Category (June 2015 - June 2020)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (June 2015 - June 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	2	580	4	62	3
1988	29	6	0	6	4	350	6	<40	3
1989	27	52	1	53	32	460	47	<40	3
1990	26	55	1	56	34	540	50	<40	3
1991	26	37	3	40	16	650	32	<40	3
1992	26	61	5	66	35	640	59	<40	3
1993	25	128	15	143	103	550	125	<40	3
1994	23	80	12	92	62	575	84	<40	3
1995	23	131	22	153	103	580	125	<40	3
1996	21	332	52	384	240	590	332	<40	3
1997	19	275	34	309	202	655	267	<40	3
1998	19	192	43	235	150	595	199	<40	3
1999	19	158	38	196	119	560	164	<40	3
2000	19	120	34	154	98	620	125	<40	3
2001	18	115	29	144	91	580	114	<40	3
2002	17	122	26	148	97	580	124	<40	3
2003	17	148	30	178	110	620	148	<40	3
2004	16	151	39	190	122	610	156	<40	3
2005	15	183	47	230	155	630	192	<40	3
2006	14	175	40	215	143	630	186	<40	3
2007	13	241	49	290	187	630	243	<40	3
2008	12	275	65	340	223	640	284	<40	3
2009	11	301	67	368	228	635	308	<40	3
2010	10	276	74	350	225	650	291	<40	3
2011	9	325	73	398	250	665	326	<40	3
2012	8	268	66	334	213	720	275	<40	3
2013	7	270	65	335	218	675	279	<40	3
2014	6	283	54	337	204	685	275	<40	3
2015	5	283	47	330	203	690	264	<40	3
2016	4	273	54	327	199	640	264	<40	3
2017	3	222	34	256	177	620	214	<40	3
2018	2	203	55	258	184	670	234	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	1	242	48	290	214	600	259	<40	3
2020	0	126	28	154	132	600	145	<40	3
Total:		6114	1250	7364					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	788	2456	<40	2146	610
FEB-2019	7368	797	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	797	2141	<40	1746	610
MAY-2019	7416	792	2127	<40	1766	620
JUN-2019	7358	803	1926	<40	1593	620
JUL-2019	7370	813	2111	<40	1695	620
AUG-2019	7366	809	2106	<40	1621	600
SEP-2019	7338	806	2011	<40	1567	600
OCT-2019	7389	785	2140	<40	1745	620
NOV-2019	7342	780	2025	<40	1579	630
DEC-2019	7343	777	1700	<40	1289	610
JAN-2020	7357	774	2226	<40	1711	610
FEB-2020	7331	779	1882	<40	1403	626
MAR-2020	7388	770	1628	<40	1182	620
APR-2020	7415	771	770	<40	553	600
MAY-2020	7411	776	1187	<40	812	610
JUN-2020	7386	783	1559	<40	1030	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	627	193	73	73	65	350
FEB-2019	658	156	75	108	66	590
MAR-2019	629	167	74	636	61	400
APR-2019	671	157	81	<50	71	480
MAY-2019	617	201	78	87	69	450
JUN-2019	680	158	79	<40	72	530
JUL-2019	668	161	71	<40	58	525
AUG-2019	687	166	81	<40	68	515
SEP-2019	717	152	96	<40	79	580
OCT-2019	659	194	81	102	69	470
NOV-2019	680	180	69	<40	59	560
DEC-2019	666	181	58	<40	49	480
JAN-2020	641	191	71	255	46	435
FEB-2020	680	179	72	<40	58	480
MAR-2020	638	196	54	<40	37	470
APR-2020	611	212	25	107	18	575
MAY-2020	624	203	42	<50	29	490
JUN-2020	657	191	57	<40	44	485

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	627	14	20	191	159	35	13564
FEB-2019	7349	658	7	16	160	181	-15	13593
MAR-2019	7371	629	15	13	187	150	22	13613
APR-2019	7325	671	10	15	152	182	-46	13641
MAY-2019	7389	617	11	21	197	137	64	13683
JUN-2019	7329	680	14	13	136	191	-60	13704
JUL-2019	7343	668	13	13	181	164	14	13727
AUG-2019	7338	687	12	18	170	174	-5	13763
SEP-2019	7310	717	14	15	181	204	-28	13790
OCT-2019	7323	659	3	13	223	150	13	13819
NOV-2019	7316	680	9	17	165	170	-7	13852
DEC-2019	7312	666	8	12	164	156	-4	13879
JAN-2020	7329	641	10	12	182	155	17	13902
FEB-2020	7297	680	12	19	141	171	-32	13938
MAR-2020	7359	638	14	23	211	154	62	13974
APR-2020	7389	611	12	8	161	124	30	13999
MAY-2020	7391	624	10	15	130	129	2	14024
JUN-2020	7364	657	8	9	123	148	-27	14041

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	7393	0.74%	91.98%	6.56%	0.72%	100.00%
FEB-2019	54	6775	490	49	7368	0.73%	91.95%	6.65%	0.67%	100.00%
MAR-2019	60	6808	489	50	7407	0.81%	91.91%	6.60%	0.68%	100.00%
APR-2019	57	6764	489	48	7358	0.77%	91.93%	6.65%	0.65%	100.00%
MAY-2019	56	6824	491	45	7416	0.76%	92.02%	6.62%	0.61%	100.00%
JUN-2019	58	6771	481	48	7358	0.79%	92.02%	6.54%	0.65%	100.00%
JUL-2019	61	6772	489	48	7370	0.83%	91.89%	6.64%	0.65%	100.00%
AUG-2019	60	6775	481	50	7366	0.81%	91.98%	6.53%	0.68%	100.00%
SEP-2019	57	6744	486	51	7338	0.78%	91.91%	6.62%	0.70%	100.00%
OCT-2019	61	6788	488	52	7389	0.83%	91.87%	6.60%	0.70%	100.00%
NOV-2019	60	6746	486	50	7342	0.82%	91.88%	6.62%	0.68%	100.00%
DEC-2019	61	6756	478	48	7343	0.83%	92.01%	6.51%	0.65%	100.00%
JAN-2020	59	6757	485	56	7357	0.80%	91.84%	6.59%	0.76%	100.00%
FEB-2020	58	6738	476	59	7331	0.79%	91.91%	6.49%	0.80%	100.00%
MAR-2020	60	6791	486	51	7388	0.81%	91.92%	6.58%	0.69%	100.00%
APR-2020	61	6820	483	51	7415	0.82%	91.98%	6.51%	0.69%	100.00%
MAY-2020	60	6819	481	51	7411	0.81%	92.01%	6.49%	0.69%	100.00%
JUN-2020	59	6791	485	51	7386	0.80%	91.94%	6.57%	0.69%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3467 48%	7 20%	3254 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3457 48%	12 41%	3256 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	541 8%	13 45%	3306 46%
MAR-2019	6 30%	3470 48%	6 30%	3274 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3305 46%
APR-2019	12 43%	3469 48%	12 43%	3278 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3245 45%
MAY-2019	14 34%	3498 48%	14 34%	3308 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3258 45%
JUN-2019	3 14%	3479 49%	3 14%	3291 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	608 8%	16 76%	3198 45%
JUL-2019	8 36%	3504 49%	8 36%	3325 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3177 44%
AUG-2019	14 39%	3515 49%	12 33%	3340 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	630 9%	20 56%	3144 44%
SEP-2019	5 19%	3494 49%	5 19%	3318 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	653 9%	17 63%	3121 44%
OCT-2019	4 14%	3513 49%	2 7%	3331 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	668 9%	23 82%	3142 44%
NOV-2019	8 24%	3458 48%	7 21%	3281 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	728 10%	19 58%	3113 44%
DEC-2019	1 4%	3437 48%	1 4%	3259 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	13 48%	855 12%	13 48%	3051 43%
JAN-2020	2 9%	3403 47%	2 9%	3227 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 39%	1024 14%	12 52%	2962 41%
FEB-2020	3 8%	3354 47%	3 8%	3182 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	16 44%	1169 16%	17 47%	2825 40%
MAR-2020	5 14%	3326 46%	5 14%	3161 44%	1 3%	34 0%	0 0%	1 0%	0 0%	0 0%	20 56%	1326 18%	11 31%	2719 38%
APR-2020	6 24%	3301 46%	5 20%	3140 43%	1 4%	35 0%	0 0%	0 0%	0 0%	0 0%	8 32%	1404 19%	11 44%	2641 37%
MAY-2020	1 4%	3279 45%	0 0%	3117 43%	0 0%	36 0%	0 0%	0 0%	0 0%	0 0%	13 54%	1482 21%	11 46%	2604 36%
JUN-2020	5 29%	3247 45%	5 29%	3085 43%	0 0%	33 0%	0 0%	0 0%	0 0%	0 0%	4 24%	1587 22%	8 47%	2526 35%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3674	51%
MAR-2019	14	70%	3702	51%
APR-2019	16	57%	3662	51%
MAY-2019	27	66%	3689	51%
JUN-2019	18	86%	3643	51%
JUL-2019	14	64%	3650	51%
AUG-2019	22	61%	3626	51%
SEP-2019	22	81%	3622	51%
OCT-2019	24	86%	3663	51%
NOV-2019	25	76%	3671	51%
DEC-2019	26	96%	3713	52%
JAN-2020	21	91%	3762	52%
FEB-2020	33	92%	3781	53%
MAR-2020	30	83%	3855	54%
APR-2020	19	76%	3893	54%
MAY-2020	23	96%	3920	54%
JUN-2020	12	71%	3933	55%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1097 40%	11 92%	1475 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1069 40%	9 82%	1472 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1486 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1477 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1033 39%	11 92%	1478 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1001 39%	9 100%	1464 57%	0 0%	119 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	981 38%	6 100%	1482 58%	0 0%	111 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	968 38%	11 92%	1459 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	954 37%	12 92%	1481 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	957 37%	13 93%	1489 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	940 37%	3 100%	1469 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	923 37%	7 100%	1466 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1435 60%	0 0%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
APR-2020	0 0%	2 0%	0 0%	839 36%	4 80%	1415 60%	1 20%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAY-2020	0 0%	2 0%	1 10%	835 36%	9 90%	1415 60%	0 0%	90 4%	0 0%	0 0%	0 0%	0 0%	0 0%	6 0%
JUN-2020	0 0%	2 0%	2 33%	813 35%	4 67%	1391 61%	0 0%	86 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%
MAY-2020	0	0%	0	0%
JUN-2020	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0 0%	1 0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0 0%	1 0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 13%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	540 36%	0 0%	194 13%	0 0%	453 30%	1 50%	305 20%
JUN-2020	0 0%	1 0%	2 100%	527 36%	0 0%	190 13%	0 0%	449 30%	0 0%	306 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2429 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2431 63%	5 23%	726 19%	0 0%	40 1%	1 5%	651 17%
MAR-2019	0 0%	27 1%	8 62%	2479 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2493 64%	3 21%	736 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2554 64%	6 21%	746 19%	0 0%	37 1%	3 11%	634 16%
JUN-2019	0 0%	27 1%	10 77%	2556 65%	3 23%	743 19%	0 0%	37 1%	0 0%	624 16%
JUL-2019	0 0%	27 1%	13 81%	2603 65%	3 19%	755 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2647 65%	1 4%	755 19%	0 0%	36 1%	3 11%	625 15%
SEP-2019	0 0%	28 1%	7 47%	2648 65%	6 40%	757 19%	0 0%	37 1%	2 13%	627 15%
OCT-2019	0 0%	28 1%	13 87%	2717 66%	1 7%	758 18%	0 0%	34 1%	1 7%	628 15%
NOV-2019	3 13%	88 2%	16 70%	2741 65%	4 17%	770 18%	0 0%	33 1%	0 0%	621 15%
DEC-2019	12 63%	230 5%	6 32%	2717 64%	1 5%	744 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	421 10%	7 39%	2688 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2645 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2624 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	829 18%	6 43%	2591 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	912 20%	6 33%	2562 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1024 22%	9 69%	2543 55%	0 0%	583 13%	1 8%	28 1%	0 0%	538 12%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1738	23.62	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1712	23.23	1427	19.36	3236	43.91	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1697	23.13	1361	18.55	3298	44.94	93	1.27	51	0.70	838	11.42
OCT-2019	1702	23.03	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1666	22.69	1272	17.32	3424	46.64	91	1.24	50	0.68	839	11.43
DEC-2019	1643	22.38	1248	17.00	3484	47.45	92	1.25	48	0.65	828	11.28
JAN-2020	1616	21.97	1209	16.43	3563	48.43	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3646	49.73	85	1.16	59	0.80	814	11.10
MAR-2020	1541	20.86	1134	15.35	3755	50.83	85	1.15	51	0.69	822	11.13
APR-2020	1525	20.57	1128	15.21	3811	51.40	85	1.15	51	0.69	815	10.99
MAY-2020	1515	20.44	1114	15.03	3835	51.75	83	1.12	51	0.69	813	10.97
JUN-2020	1462	19.79	1088	14.73	3889	52.65	83	1.12	51	0.69	813	11.01

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12252	3830
FEB-2019	12260	3829
MAR-2019	12290	3859
APR-2019	12316	3882
MAY-2019	12332	3883
JUN-2019	12332	3888
JUL-2019	12349	3903
AUG-2019	12381	3920
SEP-2019	12400	3938
OCT-2019	12434	3962
NOV-2019	12456	3971
DEC-2019	12480	3986
JAN-2020	12535	4032
FEB-2020	12566	4049
MAR-2020	12566	4039
APR-2020	12544	4015
MAY-2020	12535	4004
JUN-2020	12519	3988

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
June 2020

N = 7386

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

June 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	7	7	*
	35-49	9	10	*
	50+	27	39	*
	Total HSDA:	43	56	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	98	58	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	368	499	282	
THOMPSON/CARIBOO/ SHUSWAP	20-34	18	18	12
	35-49	70	75	57
	50+	110	179	85
	Total HSDA:	198	272	154
Total HA:		683	925	523

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		683	925	523

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	544	737	420
Female	139	188	103

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	523	55	620	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	21	13
	5 years or more	10	6
	<5 years	12	10
	Total HSDA:	43	29
KOOTENAY BOUNDARY	10 years or more	47	36
	5 years or more	16	12
	<5 years	11	10
	Total HSDA:	74	58
OKANAGAN	10 years or more	230	168
	5 years or more	76	64
	<5 years	62	50
	Total HSDA:	368	282
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	112	83
	5 years or more	44	40
	<5 years	42	31
	Total HSDA:	198	154
Total HA:		683	523

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	410	300
5 years or more	146	122
<5 years	127	101
Total HA:	683	523

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	14	25
KOOTENAY BOUNDARY	73	123	26	46
OKANAGAN	224	935	60	284
THOMPSON/CARIBOO/SHUSWAP	140	521	36	136
Total:	483	1643	136	491

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	93

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	33	35	28
	35-49	97	106	73
	50+	244	321	191
	Total HSDA:	380	468	298
FRASER NORTH	0-19	6	6	*
	20-34	122	122	*
	35-49	337	364	*
	50+	584	916	*
	Total HSDA:	1049	1408	794
FRASER SOUTH	0-19	5	5	*
	20-34	113	115	*
	35-49	327	370	*
	50+	565	833	*
	Total HSDA:	1010	1323	816
Total HA:		2439	3199	1908

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	11
	20-34	268	272	194
	35-49	761	840	601
	50+	1393	2070	1102
Total HA:		2439	3199	1908

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1849	2449	1459
Female	590	750	449

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1908	52	630	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	225	177
	5 years or more	76	60
	<5 years	79	61
	Total HSDA:	380	298
FRASER NORTH	10 years or more	591	415
	5 years or more	262	218
	<5 years	196	161
	Total HSDA:	1049	794
FRASER SOUTH	10 years or more	581	460
	5 years or more	219	171
	<5 years	210	185
	Total HSDA:	1010	816
Total HA:		2439	1908

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1397	1052
	5 years or more	557	449
	<5 years	485	407
Total HA:		2439	1908

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	141	512	30	53
FRASER NORTH	251	1578	49	228
FRASER SOUTH	219	1583	49	488
Total:	611	3673	128	769

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	197
FRASER NORTH	655
FRASER SOUTH	442
Total:	1294

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		342	492
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		183	232
VANCOUVER	0-19	18	18	7
	20-34	451	466	306
	35-49	1357	1519	962
	50+	2857	4913	2069
	Total HSDA:	4683	6916	3344
Total HA:		5208	7640	3766

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	9
	20-34	510	526	349
	35-49	1482	1655	1059
	50+	3194	5437	2349
Total HA:		5208	7640	3766

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4602	6711	3310
Female	604	927	456

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3766	54	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	191	154
	5 years or more	89	74
	<5 years	62	56
	Total HSDA:	342	284
RICHMOND	10 years or more	103	71
	5 years or more	37	28
	<5 years	43	39
	Total HSDA:	183	138
VANCOUVER	10 years or more	2875	1966
	5 years or more	1077	787
	<5 years	731	591
	Total HSDA:	4683	3344
Total HA:		5208	3766

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3169	2191
	5 years or more	1203	889
	<5 years	836	686
Total HA:		5208	3766

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	178	403	56	88
RICHMOND	44	291	11	92
VANCOUVER	622	10945	211	5271
Total:	844	11639	278	5451

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	92

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		334	470
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		128	170
SOUTH VANCOUVER ISLAND	20-34	75	79	54
	35-49	203	235	149
	50+	472	751	366
	Total HSDA:	750	1065	569
Total HA:		1212	1705	942

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1212	1705	942

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1006	1409	787
Female	206	296	155

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	942	55	580	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	192	158
	5 years or more	73	58
	<5 years	69	53
	Total HSDA:	334	269
NORTH VANCOUVER ISLAND	10 years or more	73	60
	5 years or more	37	29
	<5 years	18	15
	Total HSDA:	128	104
SOUTH VANCOUVER ISLAND	10 years or more	435	309
	5 years or more	164	137
	<5 years	151	123
	Total HSDA:	750	569
Total HA:		1212	942

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	700	527
	5 years or more	274	224
	<5 years	238	191
Total HA:		1212	942

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	199	874	78	193
NORTH VANCOUVER ISLAND	147	261	50	79
SOUTH VANCOUVER ISLAND	212	1813	46	559
Total:	558	2948	174	831

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	50
NORTH VANCOUVER ISLAND	43
SOUTH VANCOUVER ISLAND	115
Total:	208

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	20-34	9	10	5
	35-49	16	32	11
	50+	43	67	36
	Total HSDA:	68	109	52
NORTHERN INTERIOR	0-19	5	5	*
	20-34	23	24	*
	35-49	71	88	*
	50+	91	156	*
	Total HSDA:	190	273	139
Total HA:		298	430	216

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	33	35	*
	35-49	107	142	*
	50+	152	247	*
Total HA:		298	430	216

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	265	131
Female	117	165	85

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	216	52	550	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	14	*
	<5 years	5	*
	Total HSDA:	40	25
NORTH WEST	10 years or more	34	25
	5 years or more	22	17
	<5 years	12	10
	Total HSDA:	68	52
NORTHERN INTERIOR	10 years or more	79	59
	5 years or more	63	46
	<5 years	48	34
	Total HSDA:	190	139
Total HA:		298	216

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	134	96
5 years or more	99	72
<5 years	65	48
Total HA:	298	216

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	42	64	8	9
NORTH WEST	83	164	18	35
NORTHERN INTERIOR	115	454	19	187
Total:	240	682	45	231

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	11
Total:	37

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	25	41	15
	THOMPSON/CARIBOO/SHUSWAP	27	49	23
	Total HA:	64	109	49
FRASER	FRASER EAST	37	47	32
	FRASER NORTH	53	89	45
	FRASER SOUTH	81	114	63
	Total HA:	171	250	140
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	24	47	22
	RICHMOND	9	14	7
	VANCOUVER	481	865	377
	Total HA:	514	926	406
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	80	43
	NORTH VANCOUVER ISLAND	20	29	18
	SOUTH VANCOUVER ISLAND	42	86	34
	Total HA:	113	195	95
NORTHERN	NORTH EAST	11	13	10
	NORTH WEST	26	57	17
	NORTHERN INTERIOR	74	113	61
	Total HA:	111	183	88
Total:		973	1663	778

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	612	1065	485
Female	361	598	293

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	778	52	500	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

